BR112022001255A2 - Métodos de tratamento de distúrbios mediados por anticorpos com antagonistas de fcrn - Google Patents
Métodos de tratamento de distúrbios mediados por anticorpos com antagonistas de fcrnInfo
- Publication number
- BR112022001255A2 BR112022001255A2 BR112022001255A BR112022001255A BR112022001255A2 BR 112022001255 A2 BR112022001255 A2 BR 112022001255A2 BR 112022001255 A BR112022001255 A BR 112022001255A BR 112022001255 A BR112022001255 A BR 112022001255A BR 112022001255 A2 BR112022001255 A2 BR 112022001255A2
- Authority
- BR
- Brazil
- Prior art keywords
- methods
- antibody
- fcr
- present
- mediated disorders
- Prior art date
Links
- 239000005557 antagonist Substances 0.000 title abstract 6
- 238000000034 method Methods 0.000 title abstract 6
- 208000037908 antibody-mediated disorder Diseases 0.000 title abstract 3
- 101150050927 Fcgrt gene Proteins 0.000 title abstract 2
- 238000002059 diagnostic imaging Methods 0.000 abstract 2
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- 229920001184 polypeptide Polymers 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/524—CH2 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Optics & Photonics (AREA)
- Physics & Mathematics (AREA)
- Transplantation (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
Abstract
métodos de tratamento de distúrbios mediados por anticorpos com antagonistas de fcrn. a presente invenção refere-se a métodos de tratamento de um distúrbio mediado por anticorpos (por exemplo, uma doença autoimune) usando um antagonista de fcrn, por exemplo, um polipeptídeo de ligação (por exemplo, um anticorpo e/ou uma imunoadesina), compreendendo um domínio fc modificado. a presente invenção também se refere a métodos de aprimoramento de diagnóstico por imagem usando um antagonista de fcrn descrito no presente relatório descritivo. a presente invenção refere-se ainda a métodos de redução da exposição de tecido normal a um anticorpo radiomarcado durante o diagnóstico por imagem usando um antagonista de fcrn descrito no presente relatório descritivo. também são fornecidos métodos que compreendem administração a um indivíduo de uma quantidade terapeuticamente eficaz de um antagonista de fcrn descrito no presente relatório descritivo.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962878541P | 2019-07-25 | 2019-07-25 | |
| PCT/US2020/043533 WO2021016571A2 (en) | 2019-07-25 | 2020-07-24 | Methods of treating antibody-mediated disorders with fcrn antagonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112022001255A2 true BR112022001255A2 (pt) | 2022-06-14 |
Family
ID=72087159
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112022001255A BR112022001255A2 (pt) | 2019-07-25 | 2020-07-24 | Métodos de tratamento de distúrbios mediados por anticorpos com antagonistas de fcrn |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20210024620A1 (pt) |
| EP (1) | EP4004039A2 (pt) |
| JP (1) | JP2022542884A (pt) |
| KR (1) | KR20220038432A (pt) |
| CN (1) | CN114466663A (pt) |
| AU (1) | AU2020315925A1 (pt) |
| BR (1) | BR112022001255A2 (pt) |
| CA (1) | CA3148764A1 (pt) |
| CO (1) | CO2022001164A2 (pt) |
| IL (1) | IL290101A (pt) |
| MX (1) | MX2022001038A (pt) |
| TW (1) | TW202120539A (pt) |
| WO (1) | WO2021016571A2 (pt) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20240132624A1 (en) | 2022-07-27 | 2024-04-25 | Ablynx N.V. | Polypeptides binding to a specific epitope of the neonatal fc receptor |
| US20240294651A1 (en) | 2023-01-30 | 2024-09-05 | Kymab Limited | Antibodies |
| US20240368250A1 (en) | 2023-02-17 | 2024-11-07 | Ablynx N.V. | Polypeptides binding to the neonatal fc receptor |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2126967A1 (en) | 1992-11-04 | 1994-05-11 | Anna M. Wu | Novel antibody construct |
| EP0799244A1 (en) | 1995-10-16 | 1997-10-08 | Unilever N.V. | A bifunctional or bivalent antibody fragment analogue |
| GB9524973D0 (en) | 1995-12-06 | 1996-02-07 | Lynxvale Ltd | Viral vectors |
| US20040220388A1 (en) | 2000-06-30 | 2004-11-04 | Nico Mertens | Novel heterodimeric fusion proteins |
| EP1664116A4 (en) | 2003-08-22 | 2009-06-03 | Biogen Idec Inc | IMPROVED ANTIBODIES WITH CHANGED EFFECTOR FUNCTION AND MANUFACTURING METHOD THEREFOR |
| US8802820B2 (en) * | 2004-11-12 | 2014-08-12 | Xencor, Inc. | Fc variants with altered binding to FcRn |
| WO2006130834A2 (en) * | 2005-05-31 | 2006-12-07 | Board Of Regents, The University Of Texas System | IGGl ANTIBODIES WITH MUTATED FC PORTION FOR INCREASED BINDING TO FCRN RECEPTOR AND USES THEREOF |
| US7612181B2 (en) | 2005-08-19 | 2009-11-03 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
| EP2050764A1 (en) | 2007-10-15 | 2009-04-22 | sanofi-aventis | Novel polyvalent bispecific antibody format and uses thereof |
| TWI803876B (zh) | 2011-03-28 | 2023-06-01 | 法商賽諾菲公司 | 具有交叉結合區定向之雙重可變區類抗體結合蛋白 |
| TW201326209A (zh) * | 2011-09-30 | 2013-07-01 | Chugai Pharmaceutical Co Ltd | 具有促進抗原清除之ＦｃＲｎ結合域的治療性抗原結合分子 |
| PL2992012T3 (pl) * | 2013-04-29 | 2019-12-31 | F. Hoffmann-La Roche Ag | Zmodyfikowane ludzkie przeciwciała wiążące FcRn i sposoby ich zastosowania |
| CA2946430A1 (en) * | 2014-06-12 | 2015-12-17 | F. Hoffmann-La Roche Ag | Method for selecting antibodies with modified fcrn interaction |
| CN107108720A (zh) * | 2014-11-06 | 2017-08-29 | 豪夫迈·罗氏有限公司 | 具有改变的FCRN结合的Fc区变体及其使用方法 |
| US20160264669A1 (en) * | 2015-03-09 | 2016-09-15 | Argen-X N.V. | Methods of reducing serum levels of fc-containing agents using fcrn antagonists |
| GB201618424D0 (en) * | 2016-11-01 | 2016-12-14 | Argenix Bvba | Treatment of antibody mediated disease |
| WO2018213097A1 (en) * | 2017-05-15 | 2018-11-22 | University Of Rochester | Broadly neutralizing anti-influenza monoclonal antibody and uses thereof |
| WO2019110823A1 (en) * | 2017-12-08 | 2019-06-13 | Argenx Bvba | Use of fcrn antagonists for treatment of generalized myasthenia gravis |
| JP7399880B2 (ja) * | 2018-01-26 | 2023-12-18 | ジェンザイム・コーポレーション | ＦｃＲｎへの増強された結合及び延長された半減期を有するＦｃ変異体 |
-
2020
- 2020-07-24 KR KR1020227005875A patent/KR20220038432A/ko unknown
- 2020-07-24 JP JP2022504569A patent/JP2022542884A/ja active Pending
- 2020-07-24 WO PCT/US2020/043533 patent/WO2021016571A2/en active Application Filing
- 2020-07-24 US US16/938,727 patent/US20210024620A1/en active Pending
- 2020-07-24 CA CA3148764A patent/CA3148764A1/en active Pending
- 2020-07-24 AU AU2020315925A patent/AU2020315925A1/en active Pending
- 2020-07-24 EP EP20757029.2A patent/EP4004039A2/en active Pending
- 2020-07-24 BR BR112022001255A patent/BR112022001255A2/pt unknown
- 2020-07-24 CN CN202080067562.1A patent/CN114466663A/zh active Pending
- 2020-07-24 TW TW109125184A patent/TW202120539A/zh unknown
- 2020-07-24 MX MX2022001038A patent/MX2022001038A/es unknown
-
2022
- 2022-01-24 IL IL290101A patent/IL290101A/en unknown
- 2022-02-04 CO CONC2022/0001164A patent/CO2022001164A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2021016571A3 (en) | 2021-03-04 |
| CO2022001164A2 (es) | 2022-03-08 |
| CN114466663A (zh) | 2022-05-10 |
| WO2021016571A2 (en) | 2021-01-28 |
| TW202120539A (zh) | 2021-06-01 |
| KR20220038432A (ko) | 2022-03-28 |
| MX2022001038A (es) | 2022-04-26 |
| JP2022542884A (ja) | 2022-10-07 |
| US20210024620A1 (en) | 2021-01-28 |
| IL290101A (en) | 2022-03-01 |
| AU2020315925A1 (en) | 2022-03-03 |
| EP4004039A2 (en) | 2022-06-01 |
| CA3148764A1 (en) | 2021-01-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112022001255A2 (pt) | Métodos de tratamento de distúrbios mediados por anticorpos com antagonistas de fcrn | |
| Koneczny et al. | MuSK myasthenia gravis IgG4 disrupts the interaction of LRP4 with MuSK but both IgG4 and IgG1-3 can disperse preformed agrin-independent AChR clusters | |
| BR112019021991A2 (pt) | Proteínas de ligação ao antígeno trem2 e seus usos | |
| CL2021003327A1 (es) | Anticuerpos anti - sortilina y métodos para su uso. (divisional de solicitud 202100089). | |
| BRPI0621800B8 (pt) | anticorpos que se ligam à proteína fzd10, clones de hibridoma, composições farmacêuticas, kit compreendendo os referidos anticorpos, e método para diagnose ou prognose de uma doença que é associada a homólogo fzd10 ou de uma predisposição para desenvolver a doença em um indivíduo | |
| BR112019012040A2 (pt) | anticorpo isolado ou fragmento do mesmo, composição, célula isolada, e, métodos para tratamento de câncer, para detecção da expressão de cd73 em uma amostra e para identificação de um paciente com câncer adequado para o tratamento com uma terapia anti-cd73. | |
| RU2018100822A (ru) | Антитела, специфичные к гиперфосфорилированному тау-белку, и способы их применения | |
| CN109563169A (zh) | 抗hla-g特异性抗体 | |
| AR085198A1 (es) | Composicion farmaceutica | |
| MX2022003249A (es) | Anticuerpos anti receptor del factor de necrosis tumoral 2 (tnfr2) y métodos de uso. | |
| MX2009009379A (es) | Metodos y composiciones para tratar enfermedades tumorales. | |
| BRPI0619748A8 (pt) | anticorpo monoclonal, polinucleotídeo, região variável de cadeia leve, região variável de cadeia pesada, composição, mistura, métodos para produzir um anticorpo, para preparar uma composição farmacêutica ou uma mistura, de diagnóstico de uma doença ou condição associada a amilóide, para determinar o grau de carga de placa amiloidogênica em um tecido, para diagnosticar uma predisposição para uma doença ou condição, para monitorar doença residual mínima e para prever responsabilidade de um paciente, uso de um anticorpo monoclonal e/ou uma parte funcional do mesmo e/ou uma composição farmacêutica ou uma mistura, linhagem celular de hibridoma, e, kits de teste | |
| GT200600182A (es) | Anticuerpos dirigidos contra el peptido amiloide beta y metodo que utilizan los mismos | |
| NZ596409A (en) | Anti macrophage migration inhibitory factor antibodies | |
| CO2021009693A2 (es) | Proteínas de unión a antígeno del receptor gamma anti-il2 | |
| MX2021011715A (es) | Anticuerpos contra amiloide-? con piroglutamato y usos de estos campo de la invención. | |
| MA37761A1 (fr) | Protéines de liaison à un antigène antagoniste d'un double récepteur et leurs utilisations | |
| EA202190378A1 (ru) | Антитела против ifnar1 для лечения аутоиммунных заболеваний | |
| CO2021007053A2 (es) | Métodos de tratar la oftalmopatía de graves mediante el uso de anticuerpos anti-fcrn | |
| BR112017020769A2 (pt) | anticorpo ou fragmento de ligação, seq id no:3 ou seq id no:7, conjugado de anticorpo-fármaco (adc), composição farmacêutica, processo para produzir a composição farmacêutica, kit para diagnosticar um indivíduo que sofre de um distúrbio neurodegenerativo, método para diagnosticar um indivíduo que sofre de um distúrbio neurodegenerativo, uso do anticorpo ou fragmento de ligação, uso ex vivo de um peptídeo t14, método para identificar um agente candidato, ensaio para identificar um agente, método para identificar um agente que modula | |
| PH12020551648A1 (en) | Human neuregulin-1 (nrg-1) recombinant fusion protein compositions and methods of use thereof | |
| Folmsbee et al. | The cardiac protein αT-catenin contributes to chemical-induced asthma | |
| WO2017191327A3 (en) | Her-2 binding antibodies | |
| EA202100199A1 (ru) | Моноклональные антитела, специфически связывающиеся с trbv-9 человека | |
| CL2022001984A1 (es) | Composiciones métodos para aumentar, mejorar transducción vectores de terapia génica y para eliminar, reducir inmunoglobulinas |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B154 | Notification of filing of divisional application [chapter 15.50 patent gazette] |
Free format text: O PEDIDO FOI DIVIDIDO NO BR122024014725-4 PROTOCOLO 870240060541 EM 18/07/2024 10:51. |